THERAVECTYS

TheraVectys' Lenti-HPV-07 Enrolls First Patient in Phase I/IIa Trial for HPV-Induced Cancers

• TheraVectys has initiated a Phase I/IIa clinical trial for Lenti-HPV-07, an onco-therapeutic vaccine targeting cancers induced by human papillomavirus (HPV). • The trial will evaluate the safety, immunogenicity, and preliminary efficacy of Lenti-HPV-07 in 72 patients with oropharyngeal or cervical cancers across U.S. cancer centers. • Lenti-HPV-07, a lentiviral vector-based vaccine, has demonstrated complete tumor elimination and long-lasting immune memory in preclinical studies. • The trial includes patients with recurrent/metastatic cancers and newly diagnosed cases, assessing the vaccine's impact alone and in combination with anti-PD1 therapies.